Fourteen injectors circled around him like apostles.
Apollo had the influencer following, the KOL status, and the weekly training schedule. He injected the model with practiced ease and told the room, matter-of-factly,
“Vascular occlusions happen quick. You’ll know right away.”
Fourteen injectors nodded.
He wasn’t lying. He was teaching what he believed. What he believed just hadn’t been updated in a while.Neither malicious nor reckless, he was confidently and consequentially wrong.
That’s the most dangerous place in this industry; confidence built on assumptions the literature has already dismantled.
That’s what this issue is about.
59.2%
The share of documented filler vascular events that resulted in necrosis at a clinic built specifically to prevent that outcome.
If that’s what complication specialists get…
…what are the rest of us getting?
The industry has a safety culture built on the wrong assumptions. Slow injection speed, avoid danger zones, inject small deposits, and should disaster or dissatisfaction strike – hyaluronidase to the rescue.They’re in training curricula, manufacturer materials, and the private groups where injectors go for real answers.
The published literature says something different.
A 2024 study found that product rheology, specifically viscosity, elasticity, and cross-link density, is the more significant variable. The product in the syringe is riskier than the hand holding it. Most trainings don’t teach that.
120 VAE cases at a specialized complications clinic: necrosis correlated with medial face location, not arterial territory. The culprit appears to be choke anastomoses not on any standard anatomy map.
0.3 mL to the chin. Two prior uneventful procedures. Full VO with neck involvement. 2,850 IU of hyaluronidase over 15 hours to resolve. Prior safety is survivorship bias, not skill.
That figure predates modern monophasic fillers, which may require 600–750 IU per mL. Dose alone isn’t the issue. The enzyme has to be placed inside the filler mass, not adjacent to it. Placement matters as much as quantity.
The industry hasn’t tested it, hasn’t disclosed it, and hasn’t told patients it’s possible. Emerging evidence suggests repeated deep volumization may be associated with bone resorption. That’s a conversation that’s overdue.
None of this means the industry is reckless. It means the evidence moved and the training hasn’t caught up.
The gap between what’s in the literature and what’s in the treatment room is widening. The liability window is open. What closes it? Protocols built on current evidence, training that updates when the science does, and emergency preparedness that treats a 59% necrosis rate as a system issue.
Source: Localization and Staging of Vascular Adverse Events, The Impact of Gel Parameters, Dissolving Hyaluronic Acid Filler, Hyaluronidase Use in Aesthetic Medicine, A new protocol (THIS and FAT), Vascular Occlusion Following Low-volume Chin Filler, Hyaluronic Acid-Induced Mental Bone Resorption, Medspa Valuation Multiples
Q: I always watch for blanching during injection. If a VO is happening, I’ll catch it in real time. That’s my safety net, right?
A: Sometimes. But not always.
Cross-linked HA under pressure fragments and distributes into microvasculature. A patient can leave your chair looking fine and present with Stage III ischemia 24-48 hours later. One VO case series averaged 82 hours to referral. The average referral time in one VO case series was 82 hours.
Blanching is one signal, but not the whole picture.
“Your injectors are trained. The question is…on what?”
One more question before you go.
What’s one thing happening in aesthetics that leadership isn’t paying enough attention to?
I read every response.
